E10 | The Senator Who Protected Big Pharma Just Lost His Primary. Who's Next?

E10 | The Senator Who Protected Big Pharma Just Lost His Primary. Who's Next?

On May 16th, Bill Cassidy — Chairman of the Senate Health Committee and the top Republican recipient of pharmaceutical money in the 2024 cycle — came in third in his own Republican primary. A senator who took over $1 million from Big Pharma, blocked a fast-track MFN vote, and killed his own codification bill before it ever got a hearing was sent home by the voters of Louisiana. In Episode 10, Rob Burgess uses that result as the opening argument — and then spends the rest of the episode dismantling every major industry argument standing between American patients and drug pricing reform. The innovation argument. The China argument. The supply chain argument. The price controls argument. One by one, on the merits, with the data. And then: what TrumpRx actually is, what it isn't, why the industry cooperates with it, and why MFN codification is the bill they're spending $450 million a year to prevent from ever coming due. In this episode: * Bill Cassidy: $1 million from Big Pharma, blocked MFN, killed his own bill — then lost his primary * 89% of Republican voters support MFN codification. $600 billion in projected patient savings. Why it still hasn't passed. * The innovation argument, run through 2025 financial data: $5.9 billion cut from research, $97 billion returned to shareholders, $9 billion on advertising * The China argument exposed: the same industry warning Congress about Chinese competition spent $137 billion funding pharmaceutical development inside China * The supply chain argument: the industry that offshored API manufacturing for 40 years to maximize margins is now lecturing Congress about supply chain security * The price controls argument: why MFN pricing is not socialism, it's the deal every other developed nation already has * TrumpRx: what it is, who it helps, why the industry cooperates with it, and why it doesn't threaten the pricing architecture that matters * The empty chair: why the next Senate Health Committee chairman determines whether MFN becomes permanent law or stays a voluntary program pharma can ignore * The conservative case for drug pricing accountability — markets, America First, and cronyism vs. capitalism The bottom line: The industry's math has always been about money. The reform movement's math is about votes. The votes won — in Louisiana, on a Saturday night. Every member of Congress sitting on pharmaceutical contributions should be doing the same math right now. 🔔 New episodes every week — subscribe so you don't miss one. 🌐 Get involved at BustBigPharma.com #DrugPricing #HealthcareReform #BigPharmaExposed #PharmaGreed #CorruptionWatch

REPLAY | Your Prescription Comes With A Movie Budget | Guest: Chris Faulkner

Big Pharma has so much money, they don't just buy politicians — they rent both parties. That's not a conspiracy theory. That's a quote from RFK Jr., and it's exactly what Republican strategist Chris Faulkner breaks down in this episode of Bust Big Pharma. This week's episode is a replay of a previous episode where Rob Burgess sat down with Chris — a veteran political consultant who joined the Bust Big Pharma bus tour across the Southeast — to talk about why Congress won't act on drug pricing, what the 2026 midterms mean for pharma reform, and how everyday Americans can actually move the needle, because in May of 2026, this conversation matters more than ever before. 🔔 Subscribe for new episodes every week. 🌐 Learn more at BustBigPharma.com 📧 Seen a news story pharma doesn't want covered? Email us: truth@bustbigpharma.com [truth@bustbigpharma.com]

E9 | Why Are Pharma CEOs Getting Record Raises While Scientists Get Laid Off?

In 2025, AbbVie cut its research and development budget by 29% — the steepest R&D cut of any major pharmaceutical company that year. In the same year, AbbVie's CEO received a 75% pay raise, bringing his total compensation to $32.5 million. Same company. Same year. Same pool of capital. That's where Episode 9 starts. And it only gets more specific from there. Rob Burgess follows the money through the full 2025 financial picture for the 16 largest pharmaceutical companies — the advertising budgets, the executive compensation structures, the shareholder returns, the R&D cuts, and the 22,000 jobs eliminated — and then audits the decade of leadership at PhRMA, the industry's most powerful lobbying organization, that produced these numbers. Every argument the industry makes in defense of its behavior gets examined against the data. None of them hold. In this episode: * AbbVie: 75% CEO pay raise, 29% R&D cut, workers laid off — all in the same year * The 16 largest pharma companies combined cut $5.9 billion from research in 2025 while returning $97 billion to shareholders * $9 billion in direct-to-consumer advertising in 2025 — up from $6 billion in 2020 — and how the 1997 FDA rule change made it all possible * Why Trump's September 2025 executive order on misleading drug ads and the FDA's enforcement crackdown are the right moves — and why the rulemaking needs to be codified into law * How equity-based CEO compensation is structurally designed to reward price increases over research investment * A decade-long audit of PhRMA's leadership: $305 million in lobbying, drug spending up 60%, advertising tripled, the revolving door kept spinning * The four industry arguments for high prices, examined one by one against 2025 data * Three reforms that would change the system's incentives without telling a single company to stop innovating The bottom line: The innovation argument is not a fact. It's a cover story. The financial filings say so. A decade of data says so. AbbVie says so with every allocation decision it made in 2025. 🔔 New episodes every week — subscribe so you don't miss one. 🌐 Get involved at BustBigPharma.com #DrugPricing #HealthcareReform #BigPharmaExposed #PharmaGreed #CorruptionWatch

E8 | Why Are Cancer Patients Going Bankrupt While Pharma Pockets $177 Billion?

On December 19th, 2025, 14 pharmaceutical companies shook President Trump's hand and promised most favored nation pricing. The president called it the greatest victory for patient affordability in the history of American health care. Twelve days later, those same companies raised prices on 872 drugs. Then they launched 23 new drugs at an average price of $353,000 a year. In Episode 8, Rob Burgess covers two stories that belong together. First: what actually happened to Trump's MFN deals — the price hikes, the new drug launch prices, and the $177 billion in combined profit that proves the "we need high prices to innovate" argument is a lie. Then: cancer drug pricing specifically, because 51% of American cancer patients go into debt paying for treatment, and the data says the prices have nothing to do with how well the drugs work. In this episode: * 872 drug price hikes in the first two weeks of January — from companies that had just signed MFN deals at the White House * 23 new drugs launched by MFN deal signatories at an average price of $353,000 a year — one launched at $389,100 in the US, $37,900 in Japan * $177 billion in combined profit, $97 billion back to shareholders, $34 billion in stock buybacks — from companies claiming they need high prices to survive * Why the MFN deals failed: voluntary agreements without statutory enforcement are not agreements, they're handshakes * 51% of American cancer patients go into debt paying for treatment — and peer-reviewed research finds no meaningful correlation between cancer drug prices and how well those drugs work * Keytruda: $29.5 billion in revenue, dosing questions experts say could cut costs significantly, and a patent fortress extending to 2042 * Pharma increased cancer drug advertising by 43% while cutting R&D by 29% — in the same year * The EPIC Act: pharma's current lobbying push to delay Medicare price negotiation on cancer drugs by four years The bottom line: This is not a negotiating fight. You do not negotiate your way to victory with an industry that raises prices on 872 drugs twelve days after shaking the president's hand. You legislate. Codify MFN pricing. Pass the bill. 🔔 New episodes every week — subscribe so you don't miss one. 🌐 Get involved at BustBigPharma.com #DrugPricing #HealthcareReform #BigPharmaExposed #PharmaGreed #CorruptionWatch

E7 | If Competition Drops Drug Prices 80%, Why Isn't There More of It?

Every time a drug's patent is about to expire — every time competition is about to show up and prices are about to fall — Big Pharma runs the same play. It looks different each time. But the architecture is always identical. In Episode 7, Rob Burgess walks through that playbook move by move, using the two biggest-selling drugs in pharmaceutical history to show exactly how it works. First: Humira. The best-selling drug on earth. Its core patent expired in 2016. Biosimilar competition didn't arrive until 2023. The six-year delay cost American patients $75 billion. Rob walks through every move that made it happen — 250 patents, nine pay-for-delay settlements, and a product switch timed to strand the competition before it arrived. All of it documented by the company's own internal records and a three-year congressional investigation. Then: Keytruda. Merck's cancer drug. $29.5 billion in revenue last year. Core patent expires in 2028. Nearly 300 patent applications already filed. A new subcutaneous formulation launched in 2025 with patents extending to 2042. And a CEO who told investors the whole point is to turn a patent cliff into — his words — more of a hill. In this episode: * The four moves of the patent abuse playbook: patent thickets, pay-for-delay, product hopping, and FDA citizen petition abuse * How 250 patents and nine pay-for-delay settlements kept Humira competition off the market for six years after its core patent expired * The $75 billion that delay cost American patients — documented in the company's own internal projections * How Merck is running the same play on Keytruda right now, in real time, with a 2028 patent cliff and patents extending to 2042 * The Merck CEO quote that confirms the strategy — said directly to investors in a recorded statement * Why $3.5 billion a year flows out of American patients' pockets through pay-for-delay alone, every single year * Three bipartisan bills already written, already introduced, one passed the Senate unanimously — and why none of them have moved The bottom line: This is not a side issue. It is a systematic, documented, legally sophisticated strategy to deny Americans the benefits of a free market they were promised. The Senate voted unanimously to stop it. The House needs to act. 🔔 New episodes every week — subscribe so you don't miss one. 🌐 Get involved at BustBigPharma.com #BustBigPharma #Humira #Keytruda #PatentThicket #DrugPricing #BigPharma #PharmaReform #MAHA #MakeAmericaHealthyAgain #PayForDelay #ProductHopping #DrugPriceReform #PrescriptionDrugPrices #AmericansForPharmaReform